298 related articles for article (PubMed ID: 19116377)
1. Effects of critical illness and organ failure on therapeutic argatroban dosage requirements in patients with suspected or confirmed heparin-induced thrombocytopenia.
Keegan SP; Gallagher EM; Ernst NE; Young EJ; Mueller EW
Ann Pharmacother; 2009 Jan; 43(1):19-27. PubMed ID: 19116377
[TBL] [Abstract][Full Text] [Related]
2. Argatroban therapy for heparin-induced thrombocytopenia in ICU patients with multiple organ dysfunction syndrome: a retrospective study.
Saugel B; Phillip V; Moessmer G; Schmid RM; Huber W
Crit Care; 2010; 14(3):R90. PubMed ID: 20487559
[TBL] [Abstract][Full Text] [Related]
3. Weight-based argatroban dosing nomogram for treatment of heparin-induced thrombocytopenia.
Ansara AJ; Arif S; Warhurst RD
Ann Pharmacother; 2009 Jan; 43(1):9-18. PubMed ID: 19126826
[TBL] [Abstract][Full Text] [Related]
4. Argatroban anticoagulation in intensive care patients: effects of heart failure and multiple organ system failure.
Begelman SM; Baghdasarian SB; Singh IM; Militello MA; Hursting MJ; Bartholomew JR
J Intensive Care Med; 2008; 23(5):313-20. PubMed ID: 18701526
[TBL] [Abstract][Full Text] [Related]
5. Argatroban anticoagulation in critically ill patients.
Beiderlinden M; Treschan TA; Görlinger K; Peters J
Ann Pharmacother; 2007 May; 41(5):749-54. PubMed ID: 17440009
[TBL] [Abstract][Full Text] [Related]
6. Argatroban therapy in heparin-induced thrombocytopenia with hepatic dysfunction.
Levine RL; Hursting MJ; McCollum D
Chest; 2006 May; 129(5):1167-75. PubMed ID: 16685006
[TBL] [Abstract][Full Text] [Related]
7. Safety and economic considerations of argatroban use in critically ill patients: a retrospective analysis.
Kim SC; Tran N; Schewe JC; Boehm O; Wittmann M; Graeff I; Hoeft A; Baumgarten G
J Cardiothorac Surg; 2015 Feb; 10():19. PubMed ID: 25879883
[TBL] [Abstract][Full Text] [Related]
8. Argatroban dosage requirements and outcomes in intensive care versus non-intensive care patients.
Smythe MA; Koerber JM; Forsyth LL; Priziola JL; Balasubramaniam M; Mattson JC
Pharmacotherapy; 2009 Sep; 29(9):1073-81. PubMed ID: 19698012
[TBL] [Abstract][Full Text] [Related]
9. Argatroban for anticoagulation in continuous renal replacement therapy.
Link A; Girndt M; Selejan S; Mathes A; Böhm M; Rensing H
Crit Care Med; 2009 Jan; 37(1):105-10. PubMed ID: 19050602
[TBL] [Abstract][Full Text] [Related]
10. Reduced argatroban doses after coronary artery bypass graft surgery.
Hoffman WD; Czyz Y; McCollum DA; Hursting MJ
Ann Pharmacother; 2008 Mar; 42(3):309-16. PubMed ID: 18303137
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of diagnostic tests and argatroban or lepirudin therapy in patients with suspected heparin-induced thrombocytopenia.
Kiser TH; Jung R; MacLaren R; Fish DN
Pharmacotherapy; 2005 Dec; 25(12):1736-45. PubMed ID: 16305293
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of argatroban in critically ill patients with heparin resistance: a retrospective analysis.
Treichl B; Bachler M; Lorenz I; Friesenecker B; Oswald E; Schlimp CJ; Pedross F; Fries D
Semin Thromb Hemost; 2015 Feb; 41(1):61-7. PubMed ID: 25594496
[TBL] [Abstract][Full Text] [Related]
13. Effect of renal function on argatroban therapy in heparin-induced thrombocytopenia.
Guzzi LM; McCollum DA; Hursting MJ
J Thromb Thrombolysis; 2006 Dec; 22(3):169-76. PubMed ID: 17103051
[TBL] [Abstract][Full Text] [Related]
14. Argatroban anticoagulation for heparin-induced thrombocytopenia in elderly patients.
Bartholomew JR; Pietrangeli CE; Hursting MJ
Drugs Aging; 2007; 24(6):489-99. PubMed ID: 17571914
[TBL] [Abstract][Full Text] [Related]
15. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia requiring renal replacement therapy.
Reddy BV; Grossman EJ; Trevino SA; Hursting MJ; Murray PT
Ann Pharmacother; 2005 Oct; 39(10):1601-5. PubMed ID: 16131539
[TBL] [Abstract][Full Text] [Related]
16. Argatroban versus Lepirudin in critically ill patients (ALicia): a randomized controlled trial.
Treschan TA; Schaefer MS; Geib J; Bahlmann A; Brezina T; Werner P; Golla E; Greinacher A; Pannen B; Kindgen-Milles D; Kienbaum P; Beiderlinden M
Crit Care; 2014 Oct; 18(5):588. PubMed ID: 25344113
[TBL] [Abstract][Full Text] [Related]
17. Excessive argatroban anticoagulation for heparin-induced thrombocytopenia.
Reichert MG; MacGregor DA; Kincaid EH; Dolinski SY
Ann Pharmacother; 2003 May; 37(5):652-4. PubMed ID: 12708939
[TBL] [Abstract][Full Text] [Related]
18. Argatroban pharmacokinetics and pharmacodynamics in critically ill cardiac surgical patients with suspected heparin-induced thrombocytopenia.
Keyl C; Zimmer E; Bek MJ; Wiessner M; Trenk D
Thromb Haemost; 2016 Jun; 115(6):1081-9. PubMed ID: 26792118
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of argatroban and bivalirudine in patients with suspected heparin-induced thrombocytopenia.
Vo QA; Lin JK; Tong LM
Ann Pharmacother; 2015 Feb; 49(2):178-84. PubMed ID: 25515865
[TBL] [Abstract][Full Text] [Related]
20. Comparison of bivalirudin and argatroban for the management of heparin-induced thrombocytopenia.
Skrupky LP; Smith JR; Deal EN; Arnold H; Hollands JM; Martinez EJ; Micek ST
Pharmacotherapy; 2010 Dec; 30(12):1229-38. PubMed ID: 21114390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
